Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales

Executive Summary

Johnson & Johnson had to offer steeper discounts in certain therapeutic categories like cardiovascular and metabolic disease, impacting first quarter sales. So far, the impact of a new biosimilar in the US has had minimal impact on Remicade.

Advertisement

Related Content

Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Pfizer Will Support Inflectra Launch With Dedicated Sales Force

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel